Q9NZQ7 (PD1L1_HUMAN) Homo sapiens (Human)
Programmed cell death 1 ligand 1 UniProtKBInterProSTRINGInteractive Modelling
Available Structures
62 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Complex of PD-L1 with VHH1 |
Heteromer | 1×MG; | ||||
| Assess | ||||||
| Crystal structure of human PD-L1 with monoclonal antibody avelumab |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of human PD-L1 in complex with high affinity PD-1 mutant |
Heteromer Q15116; | 1×CL; | ||||
| Assess | ||||||
| Crystal Structure of the PD-1/PD-L1 Complex |
Heteromer Q02242; | |||||
| Assess | ||||||
| Crystal strucutre of PD-L1 and 3ONJA protein |
Heteromer | |||||
| Assess | ||||||
| Human PD-L1 bound to a macrocyclic peptide which blocks the PD-1/PD-L1 interaction |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of the complex between the extracellular domains of mouse PD-1 mutant and human P… |
Heteromer Q02242; | |||||
| Assess | ||||||
| Crystal strucutre of PD-L1 and DBL2_02 designed protein binder |
Heteromer Q04338; | |||||
| Assess | ||||||
| Crystal structure of ALPN-202 (engineered CD80 vIgD) in complex with PD-L1 |
Heteromer P33681; | 2×NAG; 3×NAG; | ||||
| Assess | ||||||
| Crystal strucutre of PD-L1 and the computationally designed DBL1_03 protein binder |
Heteromer | 1×ARG; | ||||
| Assess | ||||||
| Ex silico engineering of cystine-dense peptides yielding a potent bispecific T-cell engager |
Heteromer | 1×GOL; 1×NAG; 1×SO4; 1×NA; | ||||
| Assess | ||||||
| The structure of the bispecific antibody targeted PD-L1 and 4-1BB |
Heteromer | |||||
| Assess | ||||||
| Structure of PDL1 in complex with FP28135, a Helicon Polypeptide |
Heteromer | 4×EDO; 1×WHL; | ||||
| Assess | ||||||
| Complex of PD-L1 with VHH6 |
Heteromer | 3×PEG; 1×ACY; 1×OXM; 2×EDO; 1×FMT; 1×PG4; | ||||
| Assess | ||||||
| Crystal structure of PD-L1 in complex with a VHH |
Heteromer | 3×EDO; | ||||
| Assess | ||||||
| Complex structure of JS003 and PD-L1 |
Heteromer | |||||
| Assess | ||||||
| PD-L1 in complex with durvalumab |
Heteromer | |||||
| Assess | ||||||
| PD-L1 in complex with BMS-936559 Fab |
Heteromer | |||||
| Assess | ||||||
| PD-L1 in complex with atezolizumab |
Heteromer | |||||
| Assess | ||||||
| Structure of PDL1 in complex with FP28136, a Helicon Polypeptide |
Heteromer | 1×WHL; | ||||
| Assess | ||||||
| Crystal structure of PD-L1 complexed with a nanobody at 1.7 Angstron resolution |
Heteromer | 2×NA; 3×CL; 1×SO4; | ||||
| Assess | ||||||
| Structure of the complex of human programmed death-1 (PD-1) and its ligand PD-L1. |
Heteromer Q15116; | 1×NA; | ||||
| Assess | ||||||
| Crystal structure of PD-L1 complexed with atezolizumab fab at 2.9A |
Heteromer | |||||
| Assess | ||||||
| Structure of PDL1 in complex with FP28132, a Helicon Polypeptide |
Heteromer | 1×NH2; 1×WHL; | ||||
| Assess | ||||||
| Design, modification, evaluation and cocrystal studies of novel phthalimides regulating PD-1/PD-L1 … | homo-8-mer | 4×8H7; | ||||
| Assess | ||||||
| Structure of PD-L1/small-molecule inhibitor complex | homo-4-mer | 2×8J8; | ||||
| Assess | ||||||
| Dimeric Structure of PD-L1 | homo-2-mer | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN PD-L1 | homo-2-mer | 1×CL; | ||||
| Assess | ||||||
| Structure of PD-L1 | homo-2-mer | |||||
| Assess | ||||||
| PD-L1 IgV domain V76T with fragment | homo-2-mer | 4×SO4; | ||||
| Assess | ||||||
| Structure of PD-L1/small-molecule inhibitor complex | homo-2-mer | 1×8HW; | ||||
| Assess | ||||||
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor | homo-2-mer | 1×8YZ; 1×EDO; | ||||
| Assess | ||||||
| Co-crystal structure of PD-L1 with low molecular weight inhibitor | homo-2-mer | 1×WEW; 2×CL; 2×SO4; | ||||
| Assess | ||||||
| Solubilizer tag effect on PD-L1/inhibitor binding properties for m-terphenyl derivatives | homo-2-mer | 1×WEW; 2×CL; 2×SO4; | ||||
| Assess | ||||||
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor | homo-2-mer | 1×6GX; | ||||
| Assess | ||||||
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor | homo-2-mer | 1×EDO; 1×JQT; | ||||
| Assess | ||||||
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor | homo-2-mer | 1×6GZ; | ||||
| Assess | ||||||
| PD-L1 IgV domain V76T with fragment | homo-2-mer | 1×KW7; | ||||
| Assess | ||||||
| Discovery of Novel Small-molecule Inhibitors of PD-1/PD-L1 Axis that Promotes PD-L1 Internalization… | homo-2-mer | 1×HOU; | ||||
| Assess | ||||||
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with inhibitor | homo-2-mer | 1×TK2; | ||||
| Assess | ||||||
| Co-crystal structure of human PD-L1 complexed with Compound A | homo-2-mer | 1×R81; | ||||
| Assess | ||||||
| Discovery and Crystallography Study of Novel Oxadiazole Analogs as Small Molecule PD-1/PD-L1 inhibi… | homo-2-mer | 1×AU9; | ||||
| Assess | ||||||
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with inhibitor | homo-2-mer | 1×KDW; | ||||
| Assess | ||||||
| PD-L1 IgV domain V76T with fragment | homo-2-mer | 1×KWA; | ||||
| Assess | ||||||
| Co-crystal structure of PD-L1 with low molecular weight inhibitor | homo-2-mer | 1×X1Q; | ||||
| Assess | ||||||
| Discovery of Novel PD-L1 Inhibitors That Induce Dimerization and Degradation of PD-L1 Based on Frag… | homo-2-mer | 1×I7M; | ||||
| Assess | ||||||
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor | homo-2-mer | 1×UGZ; | ||||
| Assess | ||||||
| PD-L1 IgV domain bound to fragment | homo-2-mer | 1×22L; | ||||
| Assess | ||||||
| IgV-V76T BMS compound 105 | homo-2-mer | 1×KSD; | ||||
| Assess | ||||||
| Co-crystal strucutre of PD-L1 with low molecular weight inhibitor | homo-2-mer | 1×VYC; | ||||
| Assess | ||||||
| Crystal Structure of the PD-L1 | monomer | |||||
| Assess | ||||||
| Complex structure of durvalumab-scFv/PD-L1 | monomer | |||||
| Assess | ||||||
| Structure of human PD-L1 in complex with inhibitor | monomer | |||||
| Assess | ||||||
| Structure of human PD-L1 in complex with inhibitor | monomer | |||||
| Assess | ||||||
| PD-1 binding domain from human PD-L1 | monomer | |||||
| Assess | ||||||
| Structure of human PD-L1 in complex with macrocyclic inhibitor | monomer | |||||
| Assess | ||||||
| PD-L1 IgV domain complex with macro-cyclic peptide | monomer | |||||
| Assess | ||||||
| Structure of PDL1 in complex with FP30790, a Helicon Polypeptide | monomer | 1×NH2; 1×WHL; | ||||
| Assess | ||||||
| Structure of human PD-L1 in complex with inhibitor | monomer | 3×ACT; 2×GOL; | ||||
| Assess | ||||||
| Structure of human PD-L1 in complex with inhibitor | monomer | |||||
| Assess | ||||||
| Structure of the transmembrane domain of human PD-L1 | monomer | |||||
| Assess | ||||||
| membrane-bound PD-L1-CD | monomer | |||||
| Assess | ||||||
2 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7xae.1.A | monomer | 0.81 | 100.00 | |||
| Assess | ||||||
| 4k9e.1.A | monomer | 0.57 | 14.72 | |||
| Assess | ||||||
8 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 3bis.1.A | monomer | 0.75 | 99.09 | ||
| Assess | ||||||
| Isoform 2 | 5ius.1.B | monomer | 0.62 | 99.09 | ||
| Assess | ||||||
| Isoform 2 | 7dcv.1.A | monomer | 0.58 | 93.22 | ||
| Assess | ||||||
| Isoform 2 | 6dkp.1.E | monomer | 0.51 | 21.69 | ||
| Assess | ||||||
| Isoform 3 | 7xad.4.A | monomer | 0.82 | 100.00 | ||
| Assess | ||||||
| Isoform 3 | 8dp3.1.B | monomer | 0.52 | 17.48 | ||
| Assess | ||||||
| Isoform 4 | 7xae.1.A | monomer | 0.82 | 99.13 | ||
| Assess | ||||||
| Isoform 4 | 6otc.1.C | monomer | 0.55 | 15.74 | ||
| Assess | ||||||